Skip to main content

Table 2 Drug-related adverse events reported by ≥ 5% of subjects

From: Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

Event by body system

ABC/EFV/ddI (N = 24)

ABC/EFV/ddI/HU (N = 30)

 

n (%)

n (%)

Ear, nose, and throat

  

   Nasal signs and symptoms

2 (8)

0

Endocrine and metabolic

  

   Lack of appetite

1 (4)

3 (10)

   Lipid metabolism disorders

2 (8)

2 (7)

   Weight problems

0

2 (7)

Gastrointestinal

  

   Abdominal distension

1 (4)

2 (7)

   Diarrhea

5 (21)

6 (20)

   Gaseous symptoms

0

2 (7)

   GI discomfort and pain

0

3 (10)

   Nausea

3 (13)

9 (30)

   Nausea and vomiting

1 (4)

6 (20)

Musculoskeletal

  

   Arthralgia

1 (4)

2 (7)

Neurology

  

   Abnormal dreams

5 (21)

4 (13)

   Cognitive function

2 (8)

1 (3)

   disorders

2 (8)

1 (3)

   Dizziness

1 (4)

4 (13)

   Headache

1 (4)

5 (17)

   Memory effects

0

2 (7)

   Neuropathy

1 (4)

4 (13)

   Sleep disorders

0

2 (7)

Non-site specific

  

   ABC hypersensitivity

1 (4)

3 (10)

   Malaise and fatigue

2 (8)

6 (20)

Psychiatric

  

   Depressive disorders

2 (8)

1 (3)

Skin

  

   Nail disorders

0

2 (7)

   Skin rashes

3 (13)

3 (10)

  1. Note: ABC, abacavir; ddI, didanosine; EFV, efavirenz; HU, hydroxyurea